Retroviral Replicating Vector (RRV)- Mediated Prodrug-Activator Gene Therapy for Pancreatic Cancer

• Project/Area Number: 26461936
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Hokkaido University
• Principal Investigator: Hiraoka Kei 北海道大学, 医学研究科, 客員研究員 (10719587)
• Co-Investigator(Kenkyū-buntansha): 平野 聡 北海道大学, 医学研究科, 教授 (50322813) ; 土川 貴裕 北海道大学, 大学病院, 講師 (50507572) ; 七戸 俊明 北海道大学, 医学研究科, 准教授 (70374353) ; 中村 透 北海道大学, 医学研究科, 助教 (70645796)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: レトロウイルス / プロドラッグ / 膵癌 / 遺伝子治療 / ウイルスベクター

Outline of Final Research Achievements

In the present study, we are developing a retroviral replicating vector (RRV)-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma. With this system, the prodrug (antifungal drug) is converted to the anticancer drug within RRV infected cells. In pancreatic cancer preclinical models, high levels of transduction were achieved and systemic administration of 5-FC resulted in significant inhibition of tumor growth.

Research Products

• [Presentation] Retroviral Replicating Vector-mediated Prodrug Activator Gene Therapy for Pancreatic Cancer (2016)
  • Author(s): 猪子和穂、平岡 圭、稲垣亮仁、高橋瑞奈、櫛引敏寛、本谷康二、中村 透、土川貴裕、七戸俊明、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
  • Organizer: 10th International Oncolytic Virus Meeting
  • Place of Presentation: Fairmont Waterfront （Canada・Vancouver）
  • Year and Date: 2016-10-01
• [Presentation] Prodrug activator gene therapy mediated by retroviral replicating vector (RRV) for pancreatic ductal adenocarcinoma (2016)
  • Author(s): 平岡 圭、猪子和穂、稲垣亮仁、高橋瑞奈、櫛引敏寛、本谷康二、中村 透、土川貴裕、七戸俊明、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
  • Organizer: 第22回日本遺伝子細胞治療学会
  • Place of Presentation: 虎ノ門ヒルズ （東京都・港区）
  • Year and Date: 2016-07-18
• [Presentation] Therapeutic efficacy of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer (2016)
  • Author(s): 猪子和穂、平岡 圭、稲垣亮仁、高橋瑞奈、櫛引敏寛、本谷康二、高野博信、佐藤彰記、中村 透、土川貴裕、七戸俊明、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
  • Organizer: ASGCT 19th Annual Meeting
  • Place of Presentation: Marriott Wardman Park （USA・Washington DC）
  • Year and Date: 2016-05-04
• [Presentation] 増殖型レトロウイルスシステムを用いた膵癌に対するプロドラッグ活性化遺伝子治療 (2016)
  • Author(s): 猪子和穂、平岡 圭、稲垣亮仁、高橋瑞奈、櫛引敏寛、本谷康二、高野博信、佐藤彰記、中村 透、土川貴裕、七戸俊明、Harry E. Gruber、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
  • Organizer: 第116回日本外科学会定期学術集会
  • Place of Presentation: 大阪国際会議場 （大阪府・大阪市）
  • Year and Date: 2016-04-14
• [Presentation] Retroviral replicating vector (RRV)-mediated prodrug activator gene therapy for pancreatic cancer (2015)
  • Author(s): 猪子和穂、平岡 圭、稲垣亮仁、高野博信、佐藤彰記、高橋瑞菜、中村 透、土川貴裕、七戸俊明、Harry E. Gruber、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
  • Organizer: 第21回日本遺伝子治療学会学術集会
  • Place of Presentation: 大阪国際会議場 （大阪府・大阪市）
  • Year and Date: 2015-07-24